Biospecimen and Pathology Core

生物显微镜和病理学核心项目摘要 生物医学和病理学核心(BPC)将为两项完整的研究提供关键的基础设施支持 项目和发展研究方案(DRP)，以及为 随后的孢子应用。这一核心将汇集结直肠癌(CRC)的肿瘤标本 具有不同种族/民族背景的案件；提供标准化的标本收集、跟踪、 加工、储存和分销；提供对最先进实验室技术的访问；并确保 将使用以社区为基础的参与性研究框架进行研究。另外， 该核心将建立一个新的、高度注释的生物谱系信息库，其中包括肿瘤组织微阵列和 来自种族/民族多样化的结直肠癌患者的肿瘤DNA和RNA可用于未来的研究和 合作。这些活动将通过完成以下具体目标来实现：1.生物武器 收藏：我们将汇集来自种族和民族特征良好的高质量生物标本 多种多样的CRC案例。具体地说，我们将从以下四个结直肠癌病例中收集840例肿瘤组织 发病率和死亡率差异很大的种族/民族人口：非裔美国人，阿拉斯加原住民， 拉美裔/拉美裔，以及非拉美裔白人。除了这些关键资源外，我们还可以访问一些 从不同种群收集不同的生物样品，以供DRP和未来的孢子项目使用。2. 生物检疫处理：我们将处理、评估、存储和跟踪来自840 CRC的所有生物检疫样本 使用LabmatrixTM的病例，这是一个成熟的、用户友好的实验室跟踪系统。这些标本将 经过详细的集中病理检查，将用于提取肿瘤RNA和DNA。3.建立 未来活动的资源：我们将创建一个新的生物谱系资料库，并附带详细的临床资料 使用为本项目收集的肿瘤样本进行注释。它将由肿瘤组织微阵列和 提取肿瘤RNA和DNA。4.数据管理：我们将获取并协调人口统计、临床、 与生物检疫相关的流行病学和结果数据，以使其价值最大化。5.拓展业务 未来研究的能力：我们将通过以下途径提供对最先进技术的访问 我们的核心与现有共享资源的集成。这将使我们能够满足DRP的需求 项目和未来全孢子研究项目。总而言之，这一核心将为 完整的项目，处于有利地位，为发展项目提供支持，并将开发一个关键的 数据和生物质库，用于未来旨在推进CRC的内部和外部合作 差异研究。

Project Summary/Abstract of the Biospecimen and Pathology Core The Biospecimen and Pathology Core (BPC) will provide key infrastructure support for the two Full Research Projects and the Developmental Research Program (DRP), as well as allow for infrastructure development for a subsequent SPORE application. This Core will bring together tumor specimens from colorectal cancer (CRC) cases with diverse racial/ethnic backgrounds; provide a standardized system for specimen collection, tracking, processing, storage, and distribution; provide access to state-of-the-art laboratory technologies; and ensure that the research will be conducted using a community-based participatory research framework. Additionally, this core will build a new, highly annotated biospecimen repository that includes tumor tissue microarrays and tumor DNA and RNA from racially/ethnically diverse CRC patients available for future studies and collaborations. These activities will be achieved through completing the following specific aims: 1. Biospecimen Collection: We will bring together high quality biospecimens from well-characterized racially and ethnically diverse CRC cases. Specifically, we will collect tumor tissue from 840 CRC cases from the following four racial/ethnic populations with vastly different incidence and mortality rates: African Americans, Alaska Natives, Hispanics/Latinos, and non-Hispanic whites. In addition to these key resources, we have access to a number of different biospecimen collections from diverse populations for DRP and future SPORE Projects. 2. Biospecimen Processing: We will process, evaluate, store, and track all biospecimens from the 840 CRC cases using LabmatrixTM, an established, user-friendly laboratory tracking system. These specimens will undergo a detailed centralized pathology review and will be used to extract tumor RNA and DNA. 3. Establish Resources for Future Activities: We will create a new biospecimen repository accompanied by detailed clinical annotation using the tumor samples assembled for this project. It will consist of tumor tissue microarrays and extracted tumor RNA and DNA. 4. Data Management: We will acquire and harmonize demographic, clinical, epidemiologic, and outcomes data associated with the biospecimens to maximize their value. 5. Expanding Capacities for Future Research: We will provide access to state-of-the-art technologies available through the integration of our Core with existing Shared Resources. This will allow us to address the needs of DRP Projects and future Full SPORE Research Projects. In summary, this core will provide critical support to both of the Full Projects, is well-positioned to provide support for Developmental Projects, and will develop a critical data and biospecimen repository for future internal and external collaborations aimed at advancing CRC disparities research.